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October 2013 stroke severity subgroups of acute ischemic stroke patients. Because only 6% of patients had OTT <70 minutes in this study, we evaluated effect of OTT≤90 minutes. This is a relevant time-point, because the number needed to treat doubles from 4.5 to 9 for patients with OTT 91 to 180, compared with OTT≤90 minutes.
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Patients and Methods
Study Setting
The current observational study is a joint project of 10 European stroke centers. The study was approved by the relevant authorities in each participating center, if required. This study was approved in the coordinating center (Helsinki) as a registry, but did not require ethical board review. Data from individual consecutive patients were collected as previously described. 4 The merged cohort included 7106 patients treated between 1998 and 2012. OTT or 3-month modified Rankin scale (mRS) values were not available for 250 patients, who were excluded. The final cohort comprised 6856 eligible patients. Excellent outcome was defined as 3-month mRS 0 to 1. None of the patients received additional therapies, such as an endovascular procedure.
Statistical Analyses
Because of non-normal distribution of all treatment delays, age, and NIHSS, data are presented as median and interquartile range. Groups were compared with the independent samples Mann-Whitney U or χ 2 test, as appropriate. First, for the whole population, we constructed a model of logistic regression with excellent outcome (and separately mortality) as dependent variable. This model included age as continuous variable, baseline NIHSS, sex, OTT, glucose level on admission, presence of symptomatic intracranial hemorrhage (sICH) according to European Cooperative Acute Stroke Study-2 (ECASS-2) criteria, and year of admission (to counteract possible effect of overall improvement in stroke care over time). Thereafter, population was divided into 3 subgroups, based on tertiles of baseline NIHSS: 0 to 6 points, 7 to 12 points, and >12 points. 3 Separately for each NIHSS subgroup, similar models of binary logistic regression were constructed, and following parameters were forced into the model: age, sex, OTT≤ 90 minutes, glucose level on admission, intracranial hemorrhage (ICH), year of admission, and also age*sex interaction to exclude confounding. Statistical significance was set at 0.05 (2-tailed). Analyses were performed on IBM SPSS version 18 (IBM Corp, Armonk, NY).
Results
Demographics and baseline characteristics are outlined in the Focusing on early versus late treatment, OTT≤90 minutes was independently associated with 3-month mRS 0 to 1 in patients with baseline NIHSS 7 to 12 (OR, 1.37; 95% CI, 1.11-1.70; P=0.004], but not in patients with NIHSS>12 (OR, 1.00; 95% CI, 0.76-1.32; P=0.99) nor NIHSS 0 to 6 (OR, 1.04; 95% CI, 0.78-1.39; P=0.80). To overcome the possible ceiling effect from spontaneous better prognosis of patients with mild symptoms (NIHSS, 0-6), in the secondary analysis, we studied association of OTT≤90 minutes with 3-month 
Discussion
We validated our single-center findings 3 on effect of early versus late thrombolysis in a cohort from 10 stroke centers. Almost 20% of all patients were treated within 90-minute OTT. In the primary analysis, thrombolysis within this time period was independently associated with excellent outcome in patients with moderate baseline stroke severity (NIHSS, 7-12), but not in patients with mild or severe symptoms. Possible explanation for this seemingly selective extra benefit may be explained by predictive effect of NIHSS>10 on presence of proximal cerebral artery occlusion, [5] [6] [7] and less likely excellent outcome in such patients.
8 NIHSS>10 is also a common cut-off in patient selection for endovascular approaches. 9 Another possible explanation is higher proportion of cardioembolism and lower proportion of small vessel disease in patients with NIHSS>12. Based on the detailed analysis of relevant parameters studied in patients treated within 90 minutes and >90 minutes (Table I in the online-only Data Supplement), we observed larger percentage of any ICH in patients with NIHSS>12 treated >90 minutes (*P<0.05), but not in case of sICH. Furthermore, there was higher proportion of females in patients with NIHSS 7 to 12 treated >90 minutes, but sex and age*sex interaction was not associated with outcome.
Our finding that patients with mild symptoms (NIHSS<7) seem to benefit less from ultra-early treatment may be explained by a ceiling effect from the spontaneously better prognosis and is supported by recently published International Stroke Trial-3 (IST-3), 10 although a smaller recent study suggested differently. 11 Patients with mild symptoms usually have small infarcted brain volumes because of peripheral vessel occlusions or central occlusions with good collaterals. In both cases, infarct volume reduction because of ultra-early treatment might be very small to be detectable by mRS. Indeed, when excellent 3-month outcome was set to mRS 0, we found an independent association of ultra-early thrombolysis in this subgroup of patient.
As opposed to our previous report, 3 we did not find any association of ultra-early thrombolysis with mortality. This may be because of the limited number of patients treated ultra-early in the current cohort. Most cases of cardioembolism were caused by atrial fibrillation, but we do not have data on more detailed analysis of other high-risk sources of cardioembolism. This higher percentage might have had influenced the effects observed; however, the proportions were very similar in subgroups of patients treated within and >90 minutes, and presence of cardioembolism did not influence the results of the primary analysis.
In conclusion, ultra-early IV thrombolysis increases the likelihood of excellent outcome in patients with moderately severe symptoms, and in secondary analysis also in those with mild symptoms. A portion of benefit might stem from lower frequencies of ICH in these patients. 12 All measures must be taken to reduce OTT as much as possible.
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